IP Library Granted Patent US 8,865,701
Granted Patent B2
US 8,865,701 · App. 13/201,570 · Granted Oct 21, 2014

Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,701
App. No.
13/201,570
Granted
Oct 21, 2014
Kind
B2
Abstract

The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Claims (46)

1. A compound of formula (I)

wherein:

R 1 is selected from the group consisting of

(1) hydrogen

(2) C 1-6 alkyl,

(3) C 3-9 cycloalkyl, and

(4) phenyl,

wherein said alkyl, cycloalkyl or phenyl R 1 moiety is optionally substituted with one or more

(a) halo,

(b) —OH,

(c) —CN,

(d) —C 1-6 alkyl

(e) —C 3-6 cycloalkyl, or

(f) —O—C 1-6 alkyl;

R 2 is hydrogen;

R 3 is selected from the group consisting of:

(1) hydrogen,

(2) C 6-10 aryl (for example, phenyl), and

(3) heteroaryl,

wherein said aryl or heteroaryl R 3 moiety is optionally substituted with one or more

(a) halo,

(b) —C 1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen, and

(c) —O—C 1-6 alkyl;

R 11 is selected from the group consisting of

(1) hydrogen

(2) C 1-6 alkyl,

(3) C 3-6 cycloalkyl, and

(4) phenyl,

wherein said alkyl, cycloalkyl or phenyl R 11 moiety is optionally substituted with one or more

(a) halo,

(b) —OH,

(c) —CN,

(d) —C 1-6 alkyl

(e) —C 3-6 cycloalkyl, or

(f) —O—C 1-6 alkyl.

2. A compound of claim 1 , wherein R 1 is selected from the group consisting of: hydrogen, phenyl (optionally substituted with halogen), and cyclohexyl.

3. A compound of claim 2 , wherein R 3 is hydrogen or unsubstituted phenyl.

4. A compound, or a pharmaceutically acceptable salt thereof, said compound having a structure:

Structure

and

5. A compound, or a pharmaceutically acceptable salt thereof, said compound having a structure:

Structure

and

6. A pharmaceutical composition, comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition, comprising a compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition, comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →